2 fuentesSeguimiento desde 15 sept, 10:30
STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
Cobertura cronológica
Primera noticia15 sept, 10:30STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients
STAT•Adam Feuerstein
Más reciente16 sept, 19:24<a href="https://www.fiercepharma.com/pharma/vera-strong-phase-3-igan-data-trutakna-intensify-kidney-disease-rivalry-otsuka" hreflang="en">Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry</a>
New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, mirroring an earlier clinical success from Otsuka’s Voyxact and heating up competition in a rapidly evolving market race.
Fierce Pharma•Angus Liu